Biomarker for Niemann Pick Type C Disease (BioNPC) (NCT01306604) | Clinical Trial Compass
WithdrawnNot Applicable
Biomarker for Niemann Pick Type C Disease (BioNPC)
Stopped: Transition to BioMetabol
Germany, India, Sri Lanka0Started 2018-08-20
Plain-language summary
Development of a new MS-based biomarker for the early and sensitive diagnosis of Niemann Pick Type C disease from Blood (plasma)
Who can participate
Age range1 Day
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
INCLUSION CRITERIA:
* Informed consent will be obtained from the patient or the parents before any study related procedures.
* Patients of both gender from one day old
* The patient has a diagnosis of Niemann Pick Type C disease or profound suspicion for Niemann Pick Type C disease
* High-grade suspicion present, if one or more criteria are valid:
Positive family anamnesis for NPC1/NPC2
Splenomegaly without identifiable cause
Hepatomegaly without identifiable cause
Neurological symptoms without identifiable cause
Psychiatric symptoms without identifiable cause
EXCLUSION CRITERIA:
* No Informed consent from the patient or the parents before any study related procedures.
* No diagnosis of NPC1/NPC2 or no valid criteria for high-grade suspicion of NPC1/ NPC2
What they're measuring
1
Development of a new MS-based biomarker for the early and sensitive diagnosis of Niemann Pick Type C disease from blood (Plasma)